Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2014-05-13 AGM Information
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Protokoll fra generalforsamling 2014
AGM Information Classification · 99% confidence The document title is "PCI Biotech: Protokoll fra generalforsamling 2014" (Minutes from the General Meeting 2014). The text explicitly states that the Ordinary General Meeting was held on May 13, 2014, and that the protocol (minutes) is attached. It also details the election of a new board member, Hilde H. Steineger. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document is short and announces the protocol, but the core content is the summary of the AGM proceedings, making AGM-R more specific than RPA or RNS.
2014-05-13 Norwegian
PCI Biotech: First quarter 2014 report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'PCI Biotech Holding ASA - First Quarter 2014' and contains detailed operational reviews, strategic outlooks, and condensed interim consolidated financial statements (Profit and Loss, Balance Sheet data). It provides substantive financial analysis for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). It is not a mere announcement (RPA) as it contains the actual financial data tables. Q1 2014
2014-05-13 English
PCI Biotech: Resultatrapport for 1.kvartal 2014
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Rapport for første kvartal 2014' (Report for the first quarter of 2014) for PCI Biotech Holding ASA. It contains detailed operational reviews, clinical trial updates, and comprehensive financial statements (Resultatregnskap) for the period ending Q1 2014. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2014
2014-05-13 Norwegian
PCI Biotech: First quarter 2014 report
Report Publication Announcement Classification · 98% confidence The document text is extremely short (468 characters) and explicitly states: 'Please find attached the first quarter 2014 report for PCI Biotech Holding ASA.' This structure—a brief announcement stating that a report is attached or available—fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim/Quarterly Report (IR) itself. The title also mentions 'First quarter 2014 report', confirming the subject matter is a periodic financial report, but the document's function here is to announce its publication.
2014-05-13 English
PCI Biotech: Resultatrapport for 1.kvartal 2014
Report Publication Announcement Classification · 98% confidence The document text is very short (467 characters) and explicitly states: 'Vedlagt er rapport for første kvartal 2014 for PCI Biotech Holding ASA.' (Attached is the report for the first quarter of 2014 for PCI Biotech Holding ASA.). This structure—a brief announcement stating that a report is attached or published, rather than containing the full report content—fits the definition of a Report Publication Announcement (RPA). The content relates to a quarterly result, but the document itself is the announcement of that result, not the comprehensive Interim Report (IR).
2014-05-13 Norwegian
PCI Biotech: Disclosure of voting rights in connection with the Annual General Meeting 13 May 2014
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly mentions 'Disclosure of voting rights in connection with the Annual General Meeting' and details the proxy voting rights received by the Chairman of the Board for the upcoming AGM on May 13, 2014. This content directly relates to the voting structure and rights associated with a general meeting, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA), even though this specific document is a pre-meeting disclosure of proxy rights rather than the final results. Since the document is short (1099 chars) and concerns voting rights related to an AGM, DVA is the most specific fit among the provided options, as it covers voting rights announcements.
2014-05-12 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.